Second Nasdaq Deficiency Hits Jasper Therapeutics — Now Fails Stockholders' Equity Rule
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.2× avg).
Summary
A second Nasdaq deficiency notice — this time for failing the $2.5 million minimum stockholders' equity rule — requires Jasper Therapeutics to submit a compliance plan by October 5, 2026.
Key Events · Legal and Risk Events · JSPR
-
Second Nasdaq Deficiency Notice
On August 21, 2026, Nasdaq notified Jasper Therapeutics that it no longer meets the $2.5 million minimum stockholders' equity requirement under Rule 5550(b)(1), based on the June 30, 2026 10-Q.
-
Compliance Plan Deadline
The company has 45 days, until October 5, 2026, to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant up to 180 days from August 21, 2026 to regain compliance.
-
Preferred Stock Conversion as Fix
Jasper intends to regain compliance by obtaining stockholder approval to convert its outstanding Non-Voting Convertible Preferred Stock into common stock at a special meeting, though no assurance is given that approval will be obtained.
-
Parallel Listing Risks
This equity deficiency runs alongside the June 9 bid-price deficiency, which carries a November 30 deadline. The company now faces two separate Nasdaq listing compliance challenges.
Analysis · JSPR · Life Sciences
A new Nasdaq deficiency notice landed on August 21, 2026, this time for failing the minimum $2.5 million stockholders' equity requirement under Rule 5550(b)(1). This is separate from the June 9 bid-price deficiency and compounds the company's listing risk. The company has until October 5, 2026 to submit a compliance plan, and it intends to regain compliance by converting its Non-Voting Convertible Preferred Stock into common stock at a special stockholder meeting. If the plan is accepted, Nasdaq can grant up to 180 days from August 21 to regain compliance. The company already faces a November 30 deadline on the bid-price issue, so the two deficiencies now run in parallel. With a market cap near $24 million and a stock price at $0.69, the equity deficiency reflects the post-merger balance sheet strain disclosed in the August 14 10-Q, which also reiterated going-concern doubts.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 896 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24M. The 52-week trading range was $0.32 to $2.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.